TY - JOUR
T1 - Long-term prescription opioid use following surgery in the US (2017–2022)
T2 - a population-based study
AU - Schoenfeld, Andrew J.
AU - Cooper, Zara
AU - Banaag, Amanda
AU - Gong, Jonathan
AU - Bryan, Matthew R.
AU - Coles, Christian
AU - Koehlmoos, Tracey P.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/12
Y1 - 2024/12
N2 - Background: Over the last decade, numerous efforts have been made to combat the opioid crisis globally. The impact of these strategies has not been adequately measured and may differ across populations depending on baseline risk. We compared changes in long-term prescription opioid use following surgery within a national US cohort, between 2017 and 2022. Methods: We used TRICARE claims data to identify individuals undergoing one of 14 representative surgical procedures. The rate of post-operative long-term prescription opioid use during 2020–22 was compared to 2017–19. We used modified Poisson regression analyses to adjust for confounding. We performed secondary analyses that accounted for interactions between the time period and race, pre-operative opioid use, surgical care setting and our proxy for socioeconomic status. Findings: Our data derived from TRICARE claims. We included 410,326 surgical events. Across both time periods, there were 213,212 females (52%), with a median age of 53 (IQR 22) and 207,188 individuals of White race (50%). The median co-morbidity index was 0 (IQR = 0). The rate of long-term post-operative opioid use was 11% in 2017–19, which reduced to 6% in 2020–22 (risk ratio [RR] 0.51; 95% CI 0.50, 0.52). Reductions were appreciated across all census divisions in the US and across all racial minorities, those of lower socioeconomic background and pre-operative chronic opioid users. Following multivariable analysis, there was a significant reduction in long-term prescription opioid use (RR 0.61; 95% CI 0.60, 0.63) after surgery in 2020–22 as compared to 2017–19. Interpretation: This investigation represents one of the largest and most comprehensive longitudinal assessments of opioid use following surgery. We found clinically relevant reductions in post-operative prescription opioid use in 2020–22 as compared to 2017–19. Given the representative nature of the study cohort, we believe these results are reflective of national trends. Funding: U.S. Department of Defense, Defense Health Agency (award # HU00012120089).
AB - Background: Over the last decade, numerous efforts have been made to combat the opioid crisis globally. The impact of these strategies has not been adequately measured and may differ across populations depending on baseline risk. We compared changes in long-term prescription opioid use following surgery within a national US cohort, between 2017 and 2022. Methods: We used TRICARE claims data to identify individuals undergoing one of 14 representative surgical procedures. The rate of post-operative long-term prescription opioid use during 2020–22 was compared to 2017–19. We used modified Poisson regression analyses to adjust for confounding. We performed secondary analyses that accounted for interactions between the time period and race, pre-operative opioid use, surgical care setting and our proxy for socioeconomic status. Findings: Our data derived from TRICARE claims. We included 410,326 surgical events. Across both time periods, there were 213,212 females (52%), with a median age of 53 (IQR 22) and 207,188 individuals of White race (50%). The median co-morbidity index was 0 (IQR = 0). The rate of long-term post-operative opioid use was 11% in 2017–19, which reduced to 6% in 2020–22 (risk ratio [RR] 0.51; 95% CI 0.50, 0.52). Reductions were appreciated across all census divisions in the US and across all racial minorities, those of lower socioeconomic background and pre-operative chronic opioid users. Following multivariable analysis, there was a significant reduction in long-term prescription opioid use (RR 0.61; 95% CI 0.60, 0.63) after surgery in 2020–22 as compared to 2017–19. Interpretation: This investigation represents one of the largest and most comprehensive longitudinal assessments of opioid use following surgery. We found clinically relevant reductions in post-operative prescription opioid use in 2020–22 as compared to 2017–19. Given the representative nature of the study cohort, we believe these results are reflective of national trends. Funding: U.S. Department of Defense, Defense Health Agency (award # HU00012120089).
KW - Epidemiology
KW - Long-term opioid use
KW - Opioid crisis
KW - Risk factors
KW - Socioeconomic status
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85211239983&partnerID=8YFLogxK
U2 - 10.1016/j.lana.2024.100948
DO - 10.1016/j.lana.2024.100948
M3 - Article
AN - SCOPUS:85211239983
SN - 2667-193X
VL - 40
JO - The Lancet Regional Health - Americas
JF - The Lancet Regional Health - Americas
M1 - 100948
ER -